Canada To Disclose Why It Says No To Certain High-Risk Devices, Drugs
This article was originally published in Clinica
As part of an ongoing transparency initiative, Health Canada has decided to make public the rationale behind its decision to reject marketing authorization applications for highest-risk medical devices, new drug submissions and supplemental drug submissions for new indications that are submitted for review by sponsors on or after May 1, 2016. Health Canada is already publishing its rationale for all positive decisions issued after April 1, 2015 in relation to these categories of devices and drugs. The rationale is published in the form regulatory decision summaries (RDS), which were introduced last year when phase I of the transparency initiative was launched.
You may also be interested in...
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.